MTBT

Overview

MTBT is an anticancer agent and p38 MAPK activator. MTBT can inhibit tumor cell proliferation, induce cell cycle arrest and apoptosis . MTBT increases the phosphorylation of histone H3 serine in cancer cells, thereby arresting the cell cycle in the M phase. The specific inhibitor of p38 MAPK , Adezmapimod ( HY-10256 ), can abrogate the cell cycle arrest induced by MTBT.

Application

Products | Products > Disease Areas > Lung Cancer | Products > Disease Areas > Neurodegenerative Disease | Products > Disease Areas > Pain | Products > Disease Areas > Digestive System Inflammation | Products > Disease Areas > Cancer | Products > Disease Areas > Neurological, Eye or Ear Disease | Products > Disease Areas > Inflammation or Immune System Disease | Products > Disease Areas > Digestive System Disease | Products > Signaling Pathways > MAPK/ERK Pathway | Products > Signaling Pathways > Apoptosis | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > p38 MAPK | Products > Signaling Pathways > Apoptosis

Product Information

• Catalog No.: HY-118034
• CAS No.: 1110905-26-4
• Molecular Formula: C14H11NO2S2
• Molecular Weight: 289.37
• Purity: 99.61%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Solubility: ≥ 2.5 mg/mL (8.64 mM); Clear solution
• Availability: In-stock

Source

Original product source